Skip to main content
NCBI home page
The American Journal of Pathology logoLink to The American Journal of Pathology
. 1996 Mar;148(3):877–887.

Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors.

M A Izquierdo 1, G L Scheffer 1, M J Flens 1, G Giaccone 1, H J Broxterman 1, C J Meijer 1, P van der Valk 1, R J Scheper 1
PMCID: PMC1861735  PMID: 8774142

Abstract

Multidrug resistance (MDR) to anticancer drugs is a major cause of treatment failure in cancer. The lung resistance protein LRP is a newly described protein related to MDR in several in vitro models. LRP has been shown to be a strong predictor of poor response to chemotherapy and prognosis in acute myeloid leukemia and in ovarian carcinoma patients. Recently, based on a 57% and 88% amino acid identity with major vault proteins from Dictyostelium discoideum and Rattus norvegicus, respectively, we identified LRP as the human major vault protein, the main component of highly conserved cellular organelles named vaults. We have studied the immunohistochemical expression of LRP in freshly frozen normal human tissues and 174 cancer specimens of 28 tumor types. LRP was broadly distributed in normal and malignant cells, but distinct patterns of expression were noticed. High LRP expression was seen in bronchus, digestive tract, renal proximal tubules, keratinocytes, macrophages, and adrenal cortex whereas varying ing levels were observed in other organs. LRP was detected in all tumor types examined, but its frequency varied, fairly reflecting the chemosensitivity of different cancers. For example, low rates of LRP positivity were seen in testicular cancer, neuroblastoma, and acute myeloid leukemia; intermediate in ovarian cancer; and high in colon, renal, and pancreatic carcinomas. The wide occurrence of LRP in normal and transformed cells in humans, its similar distribution to that of vaults in other species, as well as the high level of conservation among eukaryotic cells of both the amino acid sequence of the major vault protein and the composition and structure of vaults, suggest that vault function is important to eukaryotic cells.

Full text

PDF
877

Images in this article

880Figure 1
on p.880
883Figure 2
on p.883
883Figure 3
on p.883

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chen G., Jaffrézou J. P., Fleming W. H., Durán G. E., Sikic B. I. Prevalence of multidrug resistance related to activation of the mdr1 gene in human sarcoma mutants derived by single-step doxorubicin selection. Cancer Res. 1994 Sep 15;54(18):4980–4987. [PubMed] [Google Scholar]
  2. Chugani D. C., Kedersha N. L., Rome L. H. Vault immunofluorescence in the brain: new insights regarding the origin of microglia. J Neurosci. 1991 Jan;11(1):256–268. doi: 10.1523/JNEUROSCI.11-01-00256.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Chugani D. C., Rome L. H., Kedersha N. L. Evidence that vault ribonucleoprotein particles localize to the nuclear pore complex. J Cell Sci. 1993 Sep;106(Pt 1):23–29. doi: 10.1242/jcs.106.1.23. [DOI] [PubMed] [Google Scholar]
  4. Cole S. P., Bhardwaj G., Gerlach J. H., Mackie J. E., Grant C. E., Almquist K. C., Stewart A. J., Kurz E. U., Duncan A. M., Deeley R. G. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 1992 Dec 4;258(5088):1650–1654. doi: 10.1126/science.1360704. [DOI] [PubMed] [Google Scholar]
  5. Cordon-Cardo C., O'Brien J. P., Boccia J., Casals D., Bertino J. R., Melamed M. R. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem. 1990 Sep;38(9):1277–1287. doi: 10.1177/38.9.1974900. [DOI] [PubMed] [Google Scholar]
  6. Futscher B. W., Abbaszadegan M. R., Domann F., Dalton W. S. Analysis of MRP mRNA in mitoxantrone-selected, multidrug-resistant human tumor cells. Biochem Pharmacol. 1994 Apr 29;47(9):1601–1606. doi: 10.1016/0006-2952(94)90538-x. [DOI] [PubMed] [Google Scholar]
  7. Gervasoni J. E., Jr, Fields S. Z., Krishna S., Baker M. A., Rosado M., Thuraisamy K., Hindenburg A. A., Taub R. N. Subcellular distribution of daunorubicin in P-glycoprotein-positive and -negative drug-resistant cell lines using laser-assisted confocal microscopy. Cancer Res. 1991 Sep 15;51(18):4955–4963. [PubMed] [Google Scholar]
  8. Goldstein L. J., Pastan I., Gottesman M. M. Multidrug resistance in human cancer. Crit Rev Oncol Hematol. 1992;12(3):243–253. doi: 10.1016/1040-8428(92)90057-w. [DOI] [PubMed] [Google Scholar]
  9. Izquierdo M. A., van der Zee A. G., Vermorken J. B., van der Valk P., Beliën J. A., Giaccone G., Scheffer G. L., Flens M. J., Pinedo H. M., Kenemans P. Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J Natl Cancer Inst. 1995 Aug 16;87(16):1230–1237. doi: 10.1093/jnci/87.16.1230. [DOI] [PubMed] [Google Scholar]
  10. Kantor R. R., Giardina S. L., Bartolazzi A., Townsend A. J., Myers C. E., Cowan K. H., Longo D. L., Natali P. G. Monoclonal antibodies to glutathione S-transferase pi-immunohistochemical analysis of human tissues and cancers. Int J Cancer. 1991 Jan 21;47(2):193–201. doi: 10.1002/ijc.2910470206. [DOI] [PubMed] [Google Scholar]
  11. Kedersha N. L., Miquel M. C., Bittner D., Rome L. H. Vaults. II. Ribonucleoprotein structures are highly conserved among higher and lower eukaryotes. J Cell Biol. 1990 Apr;110(4):895–901. doi: 10.1083/jcb.110.4.895. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Kedersha N. L., Rome L. H. Isolation and characterization of a novel ribonucleoprotein particle: large structures contain a single species of small RNA. J Cell Biol. 1986 Sep;103(3):699–709. doi: 10.1083/jcb.103.3.699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kickhoefer V. A., Rome L. H. The sequence of a cDNA encoding the major vault protein from Rattus norvegicus. Gene. 1994 Dec 30;151(1-2):257–260. doi: 10.1016/0378-1119(94)90667-x. [DOI] [PubMed] [Google Scholar]
  14. Rome L., Kedersha N., Chugani D. Unlocking vaults: organelles in search of a function. Trends Cell Biol. 1991 Aug;1(2-3):47–50. doi: 10.1016/0962-8924(91)90088-q. [DOI] [PubMed] [Google Scholar]
  15. Rout M. P., Wente S. R. Pores for thought: nuclear pore complex proteins. Trends Cell Biol. 1994 Oct;4(10):357–365. doi: 10.1016/0962-8924(94)90085-x. [DOI] [PubMed] [Google Scholar]
  16. Scheffer G. L., Wijngaard P. L., Flens M. J., Izquierdo M. A., Slovak M. L., Pinedo H. M., Meijer C. J., Clevers H. C., Scheper R. J. The drug resistance-related protein LRP is the human major vault protein. Nat Med. 1995 Jun;1(6):578–582. doi: 10.1038/nm0695-578. [DOI] [PubMed] [Google Scholar]
  17. Scheper R. J., Broxterman H. J., Scheffer G. L., Kaaijk P., Dalton W. S., van Heijningen T. H., van Kalken C. K., Slovak M. L., de Vries E. G., van der Valk P. Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res. 1993 Apr 1;53(7):1475–1479. [PubMed] [Google Scholar]
  18. Schuurhuis G. J., Broxterman H. J., de Lange J. H., Pinedo H. M., van Heijningen T. H., Kuiper C. M., Scheffer G. L., Scheper R. J., van Kalken C. K., Baak J. P. Early multidrug resistance, defined by changes in intracellular doxorubicin distribution, independent of P-glycoprotein. Br J Cancer. 1991 Nov;64(5):857–861. doi: 10.1038/bjc.1991.413. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Takeda Y., Nishio K., Niitani H., Saijo N. Reversal of multidrug resistance by tyrosine-kinase inhibitors in a non-P-glycoprotein-mediated multidrug-resistant cell line. Int J Cancer. 1994 Apr 15;57(2):229–239. doi: 10.1002/ijc.2910570217. [DOI] [PubMed] [Google Scholar]
  20. Vasu S. K., Kedersha N. L., Rome L. H. cDNA cloning and disruption of the major vault protein alpha gene (mvpA) in Dictyostelium discoideum. J Biol Chem. 1993 Jul 25;268(21):15356–15360. [PubMed] [Google Scholar]
  21. Vendrik C. P., Bergers J. J., De Jong W. H., Steerenberg P. A. Resistance to cytostatic drugs at the cellular level. Cancer Chemother Pharmacol. 1992;29(6):413–429. doi: 10.1007/BF00684841. [DOI] [PubMed] [Google Scholar]
  22. Zaman G. J., Flens M. J., van Leusden M. R., de Haas M., Mülder H. S., Lankelma J., Pinedo H. M., Scheper R. J., Baas F., Broxterman H. J. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):8822–8826. doi: 10.1073/pnas.91.19.8822. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. van der Valk P., van Kalken C. K., Ketelaars H., Broxterman H. J., Scheffer G., Kuiper C. M., Tsuruo T., Lankelma J., Meijer C. J., Pinedo H. M. Distribution of multi-drug resistance-associated P-glycoprotein in normal and neoplastic human tissues. Analysis with 3 monoclonal antibodies recognizing different epitopes of the P-glycoprotein molecule. Ann Oncol. 1990;1(1):56–64. [PubMed] [Google Scholar]

Articles from The American Journal of Pathology are provided here courtesy of American Society for Investigative Pathology

RESOURCES